ArticleOncotarget2017

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).

Pierpaolo Pastina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.